B-Cell Non-Hodgkin’s Lymphoma: Epidemiology Forecast To 2027

Non-Hodgkin’s lymphoma (NHL) refers to a group of cancers that develop in the lymphatic system. In NHL, the patient’s immune system is affected by the uncontrollable growth of malignant white blood cells, resulting in the body’s inability to fight infections and other diseases. NHL accounts for 90% of all malignant lymphomas. NHL is one of the most prevalent hematologic cancers in adults and is more commonly diagnosed in developed countries. B-cell lymphomas are the most common form of NHL diagnosed in developed countries, making up approximately 80–85% of NHL cases in the US.

GlobalData epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent cases, taking into account the significant relationship between age and B-cell NHL incidence and prevalence. GlobalData epidemiologists applied country-specific incidence and prevalence rates of B-cell NHL, wherever available, to each country’s population to obtain the number of estimated diagnosed incident and prevalent cases.

The following data describes epidemiology of B-cell NHL cases. In 2017, the 7MM had 154,245 diagnosed incident cases of B-cell NHL. This is expected to increase to 183,052 diagnosed incident cases by 2027, at an Annual Growth Rate (AGR) of 1.87%. This increase is partly attributed to the moderately rising trend in incidence in the 7MM, combined with underlying demographic changes in the respective markets. In the 7MM, DLBCL was the most common subtype of B-cell NHL, followed by FL, MZL, and MCL. The US had the highest number of diagnosed incident and diagnosed prevalent cases of B-cell NHL. The development of more effective therapies, particularly for elderly patients, would improve survival and increase disease prevalence.

Scope

The B-cell Non-Hodgkin's Lymphoma (B-cell NHL) Epidemiology Report and Model provide an overview of the risk factors and global trends B-Cell Non-Hodgkin's Lymphoma in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

This report also includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 7MM: diagnosed incident cases of B-cell NHL; diagnosed prevalent cases of B-cell NHL; and diagnosed incident and prevalent cases of B-cell NHL types such as Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), and Mantle Cell Lymphoma (MCL) in these markets. Additionally, diagnosed incident cases of DLBCL, FL, MZL, and MCL are segmented according to Ann Arbor staging (stage I –IV). Diagnosed incident cases of FL based on grade (Grades 1–3) is also provided in this report.

The B-cell NHL epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The B-cell NHL Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global B-cell NHL market.

Quantify patient populations in the global B-cell NHL market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for B-cell NHL therapeutics in each of the markets covered.

Understand magnitude of B-cell NHL market by subtypes such as DLBCL, FL, MZL, and MCL.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 B-Cell NHL: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.3.1 US

3.3.2 5EU

3.3.3 Japan

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.5 Epidemiological Forecast for B-Cell NHL (2017–2027)

3.5.1 Diagnosed Incident Cases of B-Cell NHL

3.5.2 Age-Specific Diagnosed Incident Cases of B-Cell NHL

3.5.3 Sex-Specific Diagnosed Incident Cases of B-Cell NHL

3.5.4 Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL

3.5.5 Diagnosed Incident Cases of DLBCL by Cancer Staging

3.5.6 Diagnosed Incident Cases of FL by Cancer Staging

3.5.7 Diagnosed Incident Cases of MZL by Cancer Staging

3.5.8 Diagnosed Incident Cases of MCL by Cancer Staging

3.5.9 Diagnosed Incident Cases of FL by Grade

3.5.10 Diagnosed Prevalent Cases of B-Cell NHL

3.5.11 Diagnosed Prevalent Cases of DLBCL, FL, MZL, and MCL

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of the Analysis

3.6.3 Strengths of the Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologist

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About GlobalData

4.4 Contact Us

4.5 Disclaimer

List of Tables

Table 1: B-Cell NHL Cancer Stages

Table 2: Risk Factors and Comorbidities for NHL

List of Figures

Figure 1: 7MM, Diagnosed Incident Cases of B-Cell NHL, Both Sexes, Ages ≥18 Years, 2017 and 2027

Figure 2: 7MM, Age-Standardized Diagnosed Incidence of B-Cell NHL, Ages ≥18 Years, 2017

Figure 3: 7MM, Age-Standardized Diagnosed Prevalence of B-Cell NHL, Ages ≥18 Years, 2017

Figure 4: Sources Used for Diagnosed Incident Cases of B-Cell NHL

Figure 5: Sources Used for Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL

Figure 6: Sources Used for Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL by Cancer Staging

Figure 7: Sources Used for Diagnosed Incident Cases of FL by Grade

Figure 8: Sources Used for Diagnosed Prevalent Cases of B-Cell NHL

Figure 9: Sources Used for Diagnosed Prevalent Cases of DLBCL, FL, MZL, and MCL

Figure 10: 7MM, Diagnosed Incident Cases of B-Cell NHL, Men and Women, Ages ≥18 Years, 2017

Figure 11: 7MM, Age-Specific Diagnosed Incident Cases of B-Cell NHL, Men and Women, 2017

Figure 12: 7MM, Sex-Specific Diagnosed Incident Cases of B-Cell NHL, Men and Women, Ages ≥18 Years, 2017

Figure 13: 7MM, Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL, Men and Women, Ages ≥18 Years, 2017

Figure 14: 7MM, Diagnosed Incident Cases of DLBCL by Cancer Stage, Men and Women, Ages ≥18 Years, 2017

Figure 15: 7MM, Diagnosed Incident Cases of FL by Cancer Stage, Men and Women, Ages ≥18 Years, 2017

Figure 16: 7MM, Diagnosed Incident Cases of MZL by Cancer Stage, Men and Women, Ages ≥18 Years, 2017

Figure 17: 7MM, Diagnosed Incident Cases of MCL by Cancer Stage, Men and Women, Ages ≥18 Years, 2017

Figure 18: 7MM, Diagnosed Incident Cases of FL by Grade, Men and Women, Ages ≥18 Years, 2017

Figure 19: 7MM, Diagnosed Prevalent Cases of B-Cell NHL, Men and Women, ≥18 Years, 2017

Figure 20: 7MM, Diagnosed Prevalent Cases of DLBCL, FL, MZL, and MCL, Men and Women, Ages ≥18 Years, 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports